drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Fc-engineered humanized IgG1 monoclonal antibody (also known as MGA271) targeting B7-H3 (CD276); given neoadjuvantly at 15 mg/kg IV every 2 weeks for 12 weeks. Mechanism: binds B7-H3 on tumor and stromal/vascular cells, engages Fcγ receptors to drive ADCC/ADCP (possible CDC), and may alleviate B7-H3–mediated immunosuppression to enhance T-cell activity.
nci_thesaurus_concept_id
C97510
nci_thesaurus_preferred_term
Enoblituzumab
nci_thesaurus_definition
An Fc-domain optimized, humanized monoclonal antibody directed against cancer stem cells (CSCs), with potential immunomodulating and antineoplastic activities. After binding of enoblituzumab to an as of yet not elucidated target expressed on CSCs and differentiated tumor cells, this agent may induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CSCs. CSCs are tumor initiating cells that are able to self-renew and are responsible for tumor cell growth and resistance.
drug_mesh_term
Enoblituzumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
General immune activator
drug_delivery_route
Intravenous
drug_mechanism_of_action
Fc-engineered humanized IgG1 targeting B7-H3 (CD276) on tumor and stromal/vascular cells; enhances FcγR engagement to drive NK cell/macrophage-mediated ADCC and ADCP (with possible CDC), depleting B7-H3–expressing cells, and may relieve B7-H3–mediated immunosuppression to augment antitumor T‑cell responses.
drug_name
Enoblituzumab
nct_id_drug_ref
NCT06014255